These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 16825030

  • 21. Sevelamer therapy for pediatric end-stage renal disease.
    Storms LE, Chicella MF, Dice JE.
    Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
    [Abstract] [Full Text] [Related]

  • 22. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A.
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [Abstract] [Full Text] [Related]

  • 25. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA.
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
    Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV, Degaspari S, Scavone C, Kawamoto E.
    Int J Immunopathol Pharmacol; 2014 Nov; 27(1):25-35. PubMed ID: 24674676
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function.
    Heinrich T, Heidt H, Hafner V, Schmidt-Gayk H, Jenetzky E, Walter-Sack I, Mikus G, Bommer J.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2861-7. PubMed ID: 18388122
    [Abstract] [Full Text] [Related]

  • 32. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V, Damment SJ, Henderson RA.
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 37. Survival in end stage renal disease: calcium carbonate vs. sevelamer.
    Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE.
    J Clin Pharm Ther; 2007 Dec; 32(6):617-24. PubMed ID: 18021340
    [Abstract] [Full Text] [Related]

  • 38. [Pharmacologic intervention for vascular calcification].
    Segawa H, Furutani J, Miyamoto K.
    Clin Calcium; 2005 Jul; 15(7):149-54. PubMed ID: 15995312
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
    Spiegel DM, Farmer B, Smits G, Chonchol M.
    J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.